Highest-materiality recent filing
Hyperion DeFi Q1 2026 record net income $8.84M; raises FY 2026 adjusted gross profit guidance ~20%
GAAP net income $8.84M vs. loss of $39.8M in Q4 2025; non-GAAP adjusted EBITDA $19.5M.
Hyperion DeFi prices 2.78M share offering at $3.60, expects ~$10M gross
Offers 2,777,778 shares at $3.60 per share; sole underwriter Chardan Capital Markets.
Q4 revenue $496K (+64% QoQ); Adjusted Gross Profit $821K (+87% QoQ).
Hyperion DeFi reports record Q3 net income of $6.6M; initiates Q4 guidance of 31-43% QoQ growth
Net income of $6.6M vs ($7.9M) loss in Q3'24; basic EPS $0.26, diluted $0.05.
Hyperion DeFi partners with Felix, allocates 500k HYPE to launch HIP-3 perpetual futures market
Hyperion entered a Joint Validator Agreement with Kinetiq and Pier Two, staking 10,000 HYPE for a validator node on Hyperliquid.
Hyperion DeFi appoints PayPal veteran David Knox as CFO, effective immediately
David Knox, former PayPal Head of Capital Markets and Head of Finance for Global Credit & Financial Services, named CFO.
Hyperion DeFi ups ATM offering capacity to $100M; has raised ~$29M to date
Amended sales agreement with Chardan Capital Markets increases aggregate offering price from $50M to $100M.
Hyperion DeFi shareholders approve doubling authorized shares; written consent proposal fails
Authorized common shares doubled from 300M to 600M; preferred from 6M to 60M via charter amendment filed Aug 19.
Hyperion DeFi reports Q2 net loss of $8.8M, acquires >1.5M HYPE tokens
Net loss of $8.8M ($2.50 per share) vs $11.1M ($16.65) in Q2 2024; cash $7.5M as of June 30.
Eyenovia rebrands to Hyperion DeFi, ticker to HYPD; COO departs amid crypto treasury pivot
Name change from Eyenovia to Hyperion DeFi effective July 1, 2025; new ticker HYPD on Nasdaq July 3.
Eyenovia pivots to HYPE cryptocurrency treasury; launches validator with Kinetiq
Eyenovia adopts HYPE as strategic treasury asset; first US public company to do so.
Eyenovia raises $50M to acquire HYPE tokens, shifts to crypto treasury strategy; appoints new CIO
$50M PIPE for HYPE tokens; warrants could raise ~$150M more if exercised at $3.25/share.
Eyenovia Reports Q1 2025 Financial Results, Provides Merger and Optejet Development Update
Net loss narrowed to $3.5 million ($1.59 per share) versus $10.9 million ($18.75 per share) in Q1 2024.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
On June 17, 2025, the Board of Directors (the “Board”) of the Company appointed Hyunsu Jung to the position of Chief Investment Officer and to serve on the Board, effective immediately.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
Max materiality 0.85 · Median 0.70 · Most common event other_material